US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute US biotech firm NewLink Genetics' (Nasdaq: NLNK) investigational rVSV-EBOV (Ebola) vaccine candidate.
Although financial terms of the collaboration were not revealed, New Link’s shares initially gained 2.3% to $36.15, before flattening out. NewLink shares, meanwhile, have gained 60.5% in the year to date.
Just last month NewLink signed a deal with Genentech, a Roche (ROG: SIX) subsidiary, potentially worth more than $1.15 billion for the development of NLG919, NewLink's IDO pathway inhibitor (The Pharma Letter October 20). The parties also entered into a research collaboration for the discovery of next generation IDO/TDO compounds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze